PROM1 and acute kidney injury: In this study, we aimed to accurately assess the improvement of renal function in response to CD133+ human kidney cell administration in rats after cisplatin‐induced AKI, and compare the therapeutic efficacy of the CD133+ cells with a negative control population of CD133− cells.